Developing a new treatment for opioid use disorder using cebranopadol.
Official title: Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
Funded at Park Therapeutics, INC. · NIH-10897694 · Data updated 2026-11-12
This study is testing a new medication called cebranopadol to see if it can help people with opioid use disorder by managing withdrawal symptoms while reducing the chances of abuse and dependence, giving participants a potential new option for their recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Park Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Morristown, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $3,324,591 |
| NIH project number | 5UG3DA059285-02 |
| Project ID | NIH-10897694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking treatment alternatives.
✕Less likely to help
Patients who are not struggling with opioid use disorder or those who have contraindications to cebranopadol may not benefit from this research.
What this research studies
This research focuses on cebranopadol, a novel medication designed to treat opioid use disorder (OUD) by acting on two types of opioid receptors in the brain. Unlike current treatments, cebranopadol aims to reduce the risks of abuse and physical dependence while effectively managing withdrawal symptoms. The approach involves both preclinical and clinical testing to evaluate its safety and efficacy. Patients participating in this research may receive a new therapeutic option that could improve their recovery from opioid addiction.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals struggling with opioid use disorder.
How similar studies have gone: While the approach of using a dual MOP/NOP agonist is innovative, similar research has shown promise in addressing opioid addiction, suggesting potential for success.
Where this research is happening
-
Park Therapeutics, INC.
Morristown, United States Active
Researchers
- Principal investigator: Grieco, Joseph — Park Therapeutics, INC.
- Study coordinator: Grieco, Joseph
Related research
Other NIH-funded projects on the same topics.
-
Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)
A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.
-
Precise epigenetic drugs for opioid addiction
A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.
-
Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans
This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.
-
Optimizing long-acting PrEP and opioid treatment for people in jails and prisons
This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.
-
Scaling up medications for opioid use disorder in residential treatment programs
This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.
-
Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN
This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.